Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 11, Iss. 3, 2013-09 ,pp. : 203-206

Bentham Science Publishers

Access to resources Recommend Favorite

Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes

By  

Current Diabetes Reviews, Vol. 14, Iss. 6, 2018-12 ,pp. : 509-517

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

By  

Current Vascular Pharmacology, Vol. 14, Iss. 6, 2016-10 ,pp. : 494-497

Bentham Science Publishers

Access to resources Recommend Favorite

Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat

By Davis B.   Forbes J.   Thomas M.   Jerums G.   Burns W.   Kawachi H.   Allen T.   Cooper M.  

Diabetologia, Vol. 47, Iss. 1, 2004-01 ,pp. : 89-97

Springer Publishing Company

Access to resources Recommend Favorite

—to: Davis BJ, Forbes JM, Thomas MC et al. (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89–97

By Biswas S.   Lopes de Faria J.   Lopes de Faria J.  

Diabetologia, Vol. 47, Iss. 8, 2004-08 ,pp. : 1471-1471

Springer Publishing Company

Access to resources Recommend Favorite